Human tissue kallikreins as prognostic biomarkers and as potential targets for anticancer therapy

• KUEHNE W: Üeber das trypsin (enzyme des pankreas). Heidelberg Nat. Med. Verh. (1876) 1:194-198.
   Google Scholar
• NEURATH H: Evolution of proteolytic enzymes. Science (1984) 224:350-357.
   PubMed Web of Science ®Google Scholar
• NEURATH H: Proteolytic enzymes, past and present. Fed. Proc. (1985) 44:2907-2913.
   Google Scholar
• NEURATH H: Proteolytic enzymes, past and present: the second golden era. Protein Sci. (1994) 3:1734-1739.
   Google Scholar
• BARRETT AJ, RAWLINGS ND, WOESSNER JF: Handbook of Proteolytic Enzymes. 2nd Edition. Academic Press, London (2003).
   Google Scholar
• RAWLINGS ND, MORTON FR, BARRETT AJ: MEROPS – the peptidase database. Nucleic Acids Res. (2006) 34:D270-D272.
   PubMed Web of Science ®Google Scholar
• LÓPEZ-OTÍN C, OVERALL CM: Protease degradomics: a new challenge for proteomics. Nat. Rev. Mol. Cell Biol. (2002) 3:509-519.
   PubMed Web of Science ®Google Scholar
• PUENTE XS, SANCHEZ LM, OVERALL CM, LÓPEZ-OTÍN C: Human and mouse proteases: a comparative genomic approach. Nat. Rev. Genet. (2003) 4:544-558.
   PubMed Web of Science ®Google Scholar
• SEEMÜLLER E, LUPAS A, STOCK D, LÖWE J, HUBER R, BAUMEISTER W: Proteasome from Thermoplasma acidophilum: a threonine protease. Science (1995) 268:579-582.
   PubMed Web of Science ®Google Scholar
• KRAUT J: Serine proteases: structure and mechanism of catalysis. Ann. Rev. Biochem. (1977) 46:331-358.
   PubMed Web of Science ®Google Scholar
• HEDSTROM L: Serine protease mechanism and specificity. Chem. Rev. (2002) 102:4501-4524.
   PubMed Web of Science ®Google Scholar
• MATTHEWS BW, SIGLER PB, HENDERSON R, BLOW DM: Three-dimensional structure of tosyl-α-chymotrypsin. Nature (1967) 214:652-656.
   PubMed Web of Science ®Google Scholar
• SCHECHTER I, BERGER A: On the size of the active site in proteases: 1) papain. Biochem. Biophys. Res. Commun. (1967) 27:157-162.
   PubMed Web of Science ®Google Scholar
• BLOW DM: The tortuous story of Asp…His…Ser: structural analysis of α-chymotrypsin. Trends Biochem. Sci. (1997) 22:405-408.
   Google Scholar
• DODSON G, WLODAWER A: Catalytic triads and their relatives. Trends Biochem. Sci. (1998) 23:347-352.
   PubMed Web of Science ®Google Scholar
• PERONA JJ, CRAIK CS: Structural basis of substrate specificity in the serine proteases. Protein Sci. (1995) 4:337-360.
   PubMed Web of Science ®Google Scholar
• KOBLINSKI JE, AHRAM M, SLOANE BF: Unraveling the role of proteases in cancer. Clin. Chim. Acta (2000) 291:113-135.
   PubMed Web of Science ®Google Scholar
• MIGNATTI P, RIFKIN DB: Biology and biochemistry of proteinases in tumor invasion. Physiol. Rev. (1993) 73:161-195.
   PubMed Web of Science ®Google Scholar
• LIOTTA LA, STETLER-STEVENSON WG: Tumor invasion and metastasis: an imbalance of positive and negative regulation. Cancer Res. (1991) 51:S5054-S5059.
   PubMed Web of Science ®Google Scholar
• BORGOÑO CA, MICHAEL IP, DIAMANDIS EP: Human tissue kallikreins: physiologic roles and applications in cancer. Mol. Cancer Res. (2004) 2:257-280.
   PubMed Web of Science ®Google Scholar
• BORGOÑO CA, DIAMANDIS EP: The emerging roles of human kallikreins in cancer. Nat. Rev. Cancer (2004) 4:876-890.
   PubMed Web of Science ®Google Scholar
• KRAUT H, FREY EK, WERLE E: Der Nachweis eines Kreislaufhormons in der Pankreasdrüse. Hoppe-Seyler's Z. Physiol. Chem. (1930) 189:97-106.
   Google Scholar
• WERLE E: Zur Kenntnis Des Haushalts Des Kallikreins. Biochem. Z. (1934) 269:415-434.
   Google Scholar
• YOUSEF GM, DIAMANDIS EP: An overview of the kallikrein gene families in humans and other species: emerging candidate tumor markers. Clin. Biochem. (2003) 36:443-452.
   PubMed Web of Science ®Google Scholar
• BEAUBIEN G, ROSINSKI-CHUPIN I, MATTEI MG, MBIKAY M, CHRETIEN M, SEIDAH NG: Gene structure and chromosomal localization of plasma kallikrein. Biochemistry (1991) 30:1628-1635.
   PubMed Web of Science ®Google Scholar
• YOUSEF GM, LUO LY, DIAMANDIS EP: Identification of novel human kallikrein-like genes on chromosome 19q13.3-q13.4. Anticancer Res. (1999) 19:2843-2852.
   PubMed Web of Science ®Google Scholar
• HARVEY TJ, HOOPER JD, MYERS SA, STEPHENSON SA, ASHWORTH LK, CLEMENTS JA: Tissue-specific expression patterns and fine mapping of the human kallikrein (KLK) locus on proximal 19q13.4. J. Biol. Chem. (2000) 275:37397-37406.
   PubMed Web of Science ®Google Scholar
• YOUSEF GM, DIAMANDIS EP: The new human tissue kallikrein gene family: structure, function, and association to disease. Endocr. Rev. (2001) 22:184-204.
   PubMed Web of Science ®Google Scholar
• LESK AM, FORDHAM WD: Conservation and variability in the structures of serine proteinases of the chymotrypsin family. J. Mol. Biol. (1996) 258:501-537.
   PubMedGoogle Scholar
• DEBELA M, MAGDOLEN V, SCHECHTER N et al.: Specificity profiling of seven human tissue kallikreins reveals individual subsite preferences. J. Biol. Chem. (2006) 281:25678-25688.
   PubMed Web of Science ®Google Scholar
• TAN OL, WHITBREAD AK, CLEMENTS JA, DONG Y: Kallikrein-related peptidase (KLK) family mRNA variants and protein isoforms in hormone-related cancers: do they have a function? Biol. Chem. (2006) 387:697-705.
   Google Scholar
• KURLENDER L, BORGOÑO CA, MICHAEL IP et al.: A survey of alternative transcripts of human tissue kallikrein genes. Biochim. Biophys. Acta (2005) 1755:1-14.
   Google Scholar
• CLEMENTS J, HOOPER J, DONG Y, HARVEY T: The expanded human kallikrein (KLK) gene family: genomic organization, tissue-specific expression and potential functions. Biol. Chem. (2001) 382:5-14.
   PubMed Web of Science ®Google Scholar
• KOMATSU N, TAKATA M, OTSUKI N et al.: Expression and localization of tissue kallikrein mRNAs in human epidermis and appendages. J. Invest. Dermatol. (2003) 121:542-549.
   PubMed Web of Science ®Google Scholar
• YOUSEF GM, POLYMERIS ME, GRASS L et al.: Human kallikrein 5: a potential novel serum biomarker for breast and ovarian cancer. Cancer Res. (2003) 63:3958-3965.
   PubMed Web of Science ®Google Scholar
• SHAW JL, DIAMANDIS EP: Distribution of 15 human kallikreins in tissues and biological fluids. Clin. Chem. (2007) 53:1423-1432.
   PubMed Web of Science ®Google Scholar
• RIEGMAN PH, VLIETSTRA RJ, VAN DER KORPUT HA, ROMIJN JC, TRAPMAN J: Identification and androgen-regulated expression of two major human glandular kallikrein-1 (hGK-1) mRNA species. Mol. Cell. Endocrinol. (1991) 76:181-190.
   PubMed Web of Science ®Google Scholar
• YOUNG CY, ANDREWS PE, TINDALL DJ: Expression and androgenic regulation of human prostate-specific kallikreins. J. Androl. (1995) 16:97-99.
   PubMedGoogle Scholar
• LUO LY, GRASS L, DIAMANDIS EP: The normal epithelial cell-specific 1 (NES1) gene is up-regulated by steroid hormones in the breast carcinoma cell line BT-474. Anticancer Res. (2000) 20:981-986.
   PubMed Web of Science ®Google Scholar
• YOUSEF GM, LUO LY, SCHERER SW, SOTIROPOULOU G, DIAMANDIS EP: Molecular characterization of Zyme/Protease M/Neurosin (PRSS9), a hormonally regulated kallikrein-like serine protease. Genomics (1999) 62:251-259.
   PubMed Web of Science ®Google Scholar
• NELSON PS, GAN L, FERGUSON C et al.: Molecular cloning and characterization of prostase, an androgen-regulated serine protease with prostate-restricted expression. Proc. Natl. Acad. Sci. USA (1999) 96:3114-3119.
   PubMed Web of Science ®Google Scholar
• YOUSEF GM, OBIEZU CV, LUO LY, BLACK MH, DIAMANDIS EP: Prostase/KLK-L1 is a new member of the human kallikrein gene family, is expressed in prostate and breast tissues, and is hormonally regulated. Cancer Res. (1999) 59:4252-4256.
   PubMed Web of Science ®Google Scholar
• MYERS SA, CLEMENTS JA: Kallikrein 4 (KLK4), a new member of the human kallikrein gene family is up-regulated by estrogen and progesterone in the human endometrial cancer cell line, KLE. J. Clin. Endocrinol. Metab. (2001) 86:2323-2326.
   PubMed Web of Science ®Google Scholar
• ROMAN-GOMEZ J, JIMENEZ-VELASCO A, AGIRRE X et al.: The normal epithelial cell-specific 1 (NES1) gene, a candidate tumor suppressor gene on chromosome 19q13.3-4, is down-regulated by hypermethylation in acute lymphoblastic leukemia. Leukemia (2004) 18:362-365.
   PubMed Web of Science ®Google Scholar
• LI B, GOYAL J, DHAR S et al.: CpG methylation as a basis for breast tumor-specific loss of NES1/kallikrein 10 expression. Cancer Res. (2001) 61:8014-8021.
   PubMed Web of Science ®Google Scholar
• LAXMIKANTHAN G, BLABER SI, BERNETT MJ, SCARISBRICK IA, JULIANO MA, BLABER M: 1.70 Å X-ray structure of human apo kallikrein 1 – structural changes upon peptide inhibitor/substrate binding. Proteins (2005) 58:802-814.
   PubMed Web of Science ®Google Scholar
• PAMPALAKIS G, SOTIROPOULOU G: Tissue kallikrein proteolytic cascade pathways in normal physiology and cancer. Biochim. Biophys. Acta (2007) [Epub ahead of print].
   Google Scholar
• DEPERTHES D, MARCEAU F, FRENETTE G, LAZURE C, TREMBLAY RR, DUBE JY: Human kallikrein hK2 has low kininogenase activity while prostate-specific antigen (hK3) has none. Biochim. Biophys. Acta (1997) 1343:102-106.
   PubMed Web of Science ®Google Scholar
• MIKOLAJCZYK SD, MILLAR LS, MARKER KM et al.: Ala217 is important for the catalytic function and autoactivation of prostate-specific human kallikrein 2. Eur. J. Biochem. (1997) 246:440-446.
   PubMedGoogle Scholar
• LOVGREN J, RAJAKOSKI K, KARP M, LUNDWALL A, LILJA H: Activation of the zymogen form of prostate-specific antigen by human glandular kallikrein 2. Biochem. Biophy. Res. Commun. (1997) 238:549-555.
   PubMed Web of Science ®Google Scholar
• DENMEADE SR, LOVGREN J, KHAN SR, LILJA H, ISAACS JT: Activation of latent protease function of pro-hK2, but not pro-PSA, involves autoprocessing. Prostate (2001) 48:122-126.
   PubMed Web of Science ®Google Scholar
• DEPERTHES D, FRENETTE G, BRILLARD-BOURDET M et al.: Potential involvement of kallikrein hK2 in the hydrolysis of the human seminal vesicle proteins after ejaculation. J. Androl. (1996) 17:659-665.
   PubMedGoogle Scholar
• LILJA H: A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. J. Clin. Invest. (1985) 76:1899-1903.
   PubMed Web of Science ®Google Scholar
• NAM RK, ZHANG WW, TRACHTENBERG J et al.: Single nucleotide polymorphism of the human kallikrein-2 gene highly correlates with serum human kallikrein-2 levels and in combination enhances prostate cancer detection. J. Clin. Oncol. (2003) 21:2312-2319.
   PubMed Web of Science ®Google Scholar
• YANG QF, SAKURAI T, SHAN L et al.: Novel polymorphisms of prostate-specific antigen (PSA) gene associated with PSA mRNA expression in breast cancer. J. Hum. Genet. (2000) 45:363-366.
   Google Scholar
• SLIM R, TORREMOCHA F, MOREAU T et al.: Loss-of-function polymorphism of the human kallikrein gene with reduced urinary kallikrein activity. J. Am. Soc. Nephrol. (2002) 13:968-976.
   PubMed Web of Science ®Google Scholar
• HERRALA A, KURKELA R, PORVARI K, ISOMAKI R, HENTTU P, VIHKO P: Human prostate-specific glandular kallikrein is expressed as an active and an inactive protein. Clin. Chem. (1997) 43:279-284.
   PubMed Web of Science ®Google Scholar
• TSUYUKI D, GRASS L, DIAMANDIS EP: Frequent detection of mutations in the 5′ flanking region of the prostate-specific antigen gene in female breast cancer. Eur. J. Cancer (1997) 33:1851-1854.
   Google Scholar
• MAJUMDAR S, DIAMANDIS EP: The promoter and the enhancer region of the KLK 3 (prostate specific antigen) gene is frequently mutated in breast tumors and in breast carcinoma cell lines. Br. J. Cancer (1999) 79:1594-1602.
   Google Scholar
• BHARAJ BB, LUO LY, JUNG K, STEPHAN C, DIAMANDIS EP: Identification of single nucleotide polymorphisms in the human kallikrein 10 (KLK10) gene and their association with prostate, breast, testicular, and ovarian cancers. Prostate (2002) 51:35-41.
   Google Scholar
• PAL P, XI H, SUN G et al.: Tagging SNPs in the kallikrein genes 3 and 2 on 19q13 and their associations with prostate cancer in men of European origin. Hum. Genet. (2007) [Epub ahead of print].
   Google Scholar
• DIAMANDIS EP, YOUSEF GM: Human tissue kallikrein gene family: a rich source of novel disease biomarkers. Exp. Rev. Mol. Diagn. (2001) 1:182-190.
   PubMedGoogle Scholar
• DIAMANDIS EP, YOUSEF GM: Human tissue kallikreins: a family of new cancer biomarkers. Clin. Chem. (2002) 48:1198-1205.
   PubMed Web of Science ®Google Scholar
• DIAMANDIS EP, OKUI A, MITSUI S et al.: Human kallikrein 11: a new biomarker of prostate and ovarian carcinoma. Cancer Res. (2002) 62:295-300.
   PubMed Web of Science ®Google Scholar
• HAKALAHTI L, VIHKO P, HENTTU P, AUTIO-HARMAINEN H, SOINI Y, VIHKO R: Evaluation of PAP and PSA gene expression in prostatic hyperplasia and prostatic carcinoma using northern-blot analyses, in situ hybridization and immunohistochemical stainings with monoclonal and bispecific antibodies. Int. J. Cancer (1993) 55:590-597.
   PubMed Web of Science ®Google Scholar
• PETRAKI CD, GREGORAKIS AK, PAPANASTASIOU PA, KARAVANA VN, LUO LY, DIAMANDIS EP: Immunohistochemical localization of human kallikreins 6, 10 and 13 in benign and malignant prostatic tissues. Prostate Cancer Prostatic Dis. (2003) 6:223-227.
   PubMed Web of Science ®Google Scholar
• MAGKLARA A, SCORILAS A, STEPHAN C et al.: Decreased concentrations of prostate-specific antigen and human glandular kallikrein 2 in malignant versus nonmalignant prostatic tissue. Urology (2000) 56:527-532.
   PubMedGoogle Scholar
• ABRAHAMSSON PA, LILJA H, FALKMER S, WADSTROM LB: Immunohistochemical distribution of the three predominant secretory proteins in the parenchyma of hyperplastic and neoplastic prostate glands. Prostate (1988) 12:39-46.
   PubMed Web of Science ®Google Scholar
• PRETLOW TG, PRETLOW TP, YANG B et al.: Tissue concentrations of prostate-specific antigen in prostatic carcinoma and benign prostatic hyperplasia. Int. J. Cancer (1991) 49:645-649.
   PubMedGoogle Scholar
• YOUSEF GM, SCORILAS A, CHANG A et al.: Down-regulation of the human kallikrein gene 5 (KLK5) in prostate cancer tissues. Prostate (2002) 51:126-132.
   PubMed Web of Science ®Google Scholar
• YOUSEF GM, STEPHAN C, SCORILAS A et al.: Differential expression of the human kallikrein gene 14 (KLK14) in normal and cancerous prostatic tissues. Prostate (2003) 56:287-292.
   PubMed Web of Science ®Google Scholar
• STEPHAN C, YOUSEF GM, SCORILAS A et al.: Quantitative analysis of kallikrein 15 gene expression in prostate tissue. J. Urol. (2003) 169:361-364.
   PubMed Web of Science ®Google Scholar
• ABRAHAMSSON PA, LILJA H, FALKMER S, WADSTROM LB: Immunohistochemical distribution of the three predominant secretory proteins in the parenchyma of hyperplastic and neoplastic prostate glands. Prostate (1988) 12:39-46.
   PubMed Web of Science ®Google Scholar
• STEGE R, GRANDE M, CARLSTROM K, TRIBUKAIT B, POUSETTE A: Prognostic significance of tissue prostate-specific antigen in endocrine-treated prostate carcinomas. Clin. Cancer Res. (2000) 6:160-165.
   PubMed Web of Science ®Google Scholar
• KLOKK TI, KILANDER A, XI Z et al.: Kallikrein 4 is a proliferative factor that is overexpressed in prostate cancer. Cancer Res. (2007) 67:5221-5230.
   PubMed Web of Science ®Google Scholar
• NAKAMURA T, STEPHAN C, SCORILAS A, YOUSEF GM, JUNG K, DIAMANDIS EP: Quantitative analysis of hippostasin/KLK11 gene expression in cancerous and noncancerous prostatic tissues. Urology (2003) 61:1042-1046.
   PubMed Web of Science ®Google Scholar
• KWIATKOWSKI MK, RECKER F, PIIRONEN T et al.: In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic ‘gray zone’ of total PSA 4 to 10 ng/mL. Urology (1998) 52:360-365.
   PubMed Web of Science ®Google Scholar
• BORGOÑO CA, KISHI T, SCORILAS A et al.: Human kallikrein 8 protein is a favorable prognostic marker in ovarian cancer. Clin. Cancer Res. (2006) 12:1487-1493.
   PubMed Web of Science ®Google Scholar
• BORGOÑO CA, FRACCHIOLI S, YOUSEF GM et al.: Favorable prognostic value of tissue human kallikrein 11 (hK11) in patients with ovarian carcinoma. Int. J. Cancer (2003) 106:605-610.
   PubMed Web of Science ®Google Scholar
• SCORILAS A, BORGOÑO CA, HARBECK N et al.: Human kallikrein 13 protein in ovarian cancer cytosols: a new favorable prognostic marker. J. Clin. Oncol. (2004) 22:678-685.
   PubMed Web of Science ®Google Scholar
• DIAMANDIS EP, BORGOÑO CA, SCORILAS A et al.: Immunofluorometric quantification of human kallikrein 5 expression in ovarian cancer cytosols and its association with unfavorable patient prognosis. Tumour Biol. (2003) 24:299-309.
   PubMedGoogle Scholar
• SHAN SJ, SCORILAS A, KATSAROS D et al.: Unfavorable prognostic value of human kallikrein 7 quantified by ELISA in ovarian cancer cytosols. Clin. Chem. (2006) 52:1879-1886.
   PubMed Web of Science ®Google Scholar
• YOUSEF GM, MAGKLARA A, CHANG A, JUNG K, KATSAROS D, DIAMANDIS EP: Cloning of a new member of the human kallikrein gene family, KLK14, which is down-regulated in different malignancies. Cancer Res. (2001) 61:3425-3431.
   PubMed Web of Science ®Google Scholar
• YOUSEF GM, YACOUB GM, POLYMERIS ME, POPALIS C, SOOSAIPILLAI A, DIAMANDIS EP: Kallikrein gene downregulation in breast cancer. Br. J. Cancer (2004) 90:167-172.
   PubMedGoogle Scholar
• YOUSEF GM, OBIEZU CV, JUNG K, STEPHAN C, SCORILAS A, DIAMANDIS EP: Differential expression of kallikrein gene 5 in cancerous and normal testicular tissues. Urology (2002) 60:714-718.
   PubMed Web of Science ®Google Scholar
• LUO LY, RAJPERT-DE MEYTS ER, JUNG K, DIAMANDIS EP: Expression of the normal epithelial cell-specific 1 (NES1; KLK10) candidate tumor suppressor gene in normal and malignant testicular tissue. Br. J. Cancer (2001) 85:220-224.
   PubMed Web of Science ®Google Scholar
• ZHANG Y, BHAT I, ZENG M et al.: Human kallikrein 10, a predictive marker for breast cancer. Biol. Chem. (2006) 387:715-721.
   PubMed Web of Science ®Google Scholar
• KAPADIA C, GHOSH MC, GRASS L, DIAMANDIS EP: Human kallikrein 13 involvement in extracellular matrix degradation. Biochem. Biophys. Res. Commun. (2004) 323:1084-1090.
   PubMed Web of Science ®Google Scholar
• BORGOÑO CA, MICHAEL IP, SHAW JL: Expression and functional characterization of the cancer-related serine protease, human tissue kallikrein 14. J. Biol. Chem. (2007) 282:2405-2422.
   PubMed Web of Science ®Google Scholar
• CHANG A, YOUSEF GM, JUNG K, MEYTS ER, DIAMANIDS EP: Identification and molecular characterization of five novel kallikrein gene 13 (KLK13; KLK-L4) splice variants: differential expression in human testis and testicular cancer. Anticancer Res. (2001) 21:3147-3152.
   PubMed Web of Science ®Google Scholar
• SANO A, SANGAI T, MAEDA H, NAKAMURA M, HASEBE T, OCHIAI A: Kallikrein 11 expressed in human breast cancer cells releases insulin-like growth factor through degradation of IGFBP-3. Int. J. Oncol. (2007) 30:1493-1498.
   PubMedGoogle Scholar
• COHEN P, PEEHL DM, LAMSON G, ROSENFELD RG: Insulin-like growth factors (IGFs), IGF receptors, and IGF-binding proteins in primary cultures of prostate epithelial cells. J. Clin. Endocrinol. Metab. (1991) 73:401-407.
   PubMed Web of Science ®Google Scholar
• KILLIAN CS, CORRAL DA, KAWINSKI E, CONSTANTINE RI: Mitogenic response of osteoblast cells to prostate-specific antigen suggests an activation of latent TGF-β and a proteolytic modulation of cell adhesion receptors. Biochem. Biophys. Res. Commun. (1993) 192:940-947.
   PubMed Web of Science ®Google Scholar
• JOHNSON SK, RAMANI VC, HENNINGS L, HAUN RS: Kallikrein 7 enhances pancreatic cancer cell invasion by shedding E-cadherin. Cancer (2007) 109:1811-1820.
   PubMed Web of Science ®Google Scholar
• DHAR S, BHARGAVA R, YUNES M et al.: Analysis of normal epithelial cell specific-1 (NES1)/Kallikrein 10 mRNA expression by in situ hybridization, a novel marker for breast cancer. Clin. Cancer Res. (2001) 7:3393-3398.
   PubMed Web of Science ®Google Scholar
• GOYAL J, SMITH KM, COWAN JM, WAZER DE, LEE SW, BAND V: The role for NES1 serine protease as a novel tumor suppressor. Cancer Res. (1998) 58:4782-4786.
   PubMed Web of Science ®Google Scholar
• EWAN KING L, LI X, CHEIKH SAAD BOUH K, PEDNEAULT M, CHU CW: Human kallikrein 10 ELISA development and validation in breast cancer sera. Clin. Biochem. (2007) [Epub ahead of print].
   Google Scholar
• SHER YP, CHOU CC, CHOU RH et al.: Human kallikrein 8 protease confers a favorable clinical outcome in non-small cell lung cancer by suppressing tumor cell invasiveness. Cancer Res. (2006) 66:11763-11770.
   Google Scholar
• SOTIROPOULOU G, ROGAKOS V, TSETSENIS T et al.: Emerging interest in the kallikrein gene family for understanding and diagnosing cancer. Oncol. Res. (2003) 13:381-391.
   PubMed Web of Science ®Google Scholar
• HEIDTMANN HH, NETTELBECK DM, MINGELS A, JAGER R, WELKER HG, KONTERMANN RE: Generation of angiostatin-like fragments from plasminogen by prostate-specific antigen. Br. J. Cancer (1999) 81:1269-1273.
   PubMed Web of Science ®Google Scholar

Patents

• MOUNT SINAI HOSPITAL CORP.: US7199229 (2007).
   Google Scholar
• MOUNT SINAI HOSPITAL CORP.: EP1724351 (2006).
   Google Scholar
• MOUNT SINAI HOSPITAL CORP.: US7022497 (2006).
   Google Scholar
• NUVELO, INC.: EP1661986 (2006).
   Google Scholar
• INCYTE GENOMICS, INC.: US6197511 (2001).
   Google Scholar
• INCYTE GENOMICS, INC.: US2003148271 (2003).
   Google Scholar
• ORION YHTYMAE OYJ.: US6303361 (2001).
   Google Scholar
• INCYTE PHARMA, INC.: WO9803665 (1998).
   Google Scholar
• INCYTE PHARMA, INC.: US2002068341 (2002).
   Google Scholar
• MOUNT SINAI HOSPITAL CORP.: EP1159431 (2001).
   Google Scholar
• INCYTE PHARMA, INC.: US6184357 (2001).
   Google Scholar
• REMIN HOSPITAL OF SHENZHEN: CN1384199 (2002).
   Google Scholar
• TONGJI HOSPITAL: CN1412303 (2003).
   Google Scholar
• EXONHIT THERAPEUTICS: US2005112705 (2001).
   Google Scholar
• EXONHIT THERAPEUTICS: WO2004056989 (2004).
   Google Scholar
• EXONHIT THERAPEUTICS: FR2844278 (2004).
   Google Scholar
• EXONHIT THERAPEUTICS: FR2837215 (2003).
   Google Scholar
• CLEMENTS JUDITH A: US2006035219 (2006).
   Google Scholar
• BRACCO LAURENT: US2005112705 (2005).
   Google Scholar
• BRACCO LAURENT: WO2004056989 (2004).
   Google Scholar
• ISIS PHARMACEUTICALS, INC.: US2004097452 (2004).
   Google Scholar
• MOUNT SINAI HOSPITAL CORP.: WO2004021009 (2004).
   Google Scholar
• MOUNT SINAI HOSPITAL CORP.: EP1330652 (2003).
   Google Scholar
• MEDICAL UNIVERSITY OF SOUTH CAROLINA: US6747140 (2004).
   Google Scholar
• MEDICAL UNIVERSITY OF SOUTH CAROLINA: US6376182 (2002).
   Google Scholar
• HYBRITECH INC.: US6284873 (2001).
   Google Scholar
• CELL GENESYS, INC.: US6916918 (2005).
   Google Scholar
• UNIVERSITY OF MANITOBA: US7195759 (2007).
   Google Scholar
• BAYER HEALTHCARE AG.: WO2006008002 (2006).
   Google Scholar
• BAYER HEALTHCARE AG.: WO2005075662 (2005).
   Google Scholar
• BAYER HEALTHCARE AG.: EP1711828 (2006).
   Google Scholar
• BAYER HEALTHCARE AG.: EP1718759 (2006).
   Google Scholar
• BAYER HEALTHCARE AG.: WO2005080589 (2005).
   Google Scholar
• BAYER HEALTHCARE AG.: WO2005083110 (2005).
   Google Scholar
• BAYER HEALTHCARE AG.: WO2005078123 (2005).
   Google Scholar
• BAYER HEALTHCARE AG.: EP1721003 (2006).
   Google Scholar
• MOUNT SINAI HOSPITAL CORP.: EP1330652 (2003).
   Google Scholar
• BAYER HEALTHCARE AG.: WO2005078117 (2005).
   Google Scholar
• BAYER HEALTHCARE AG.: EP1718975 (2006).
   Google Scholar
• BAYER HEALTHCARE AG.: WO2005075667 (2005).
   Google Scholar
• BAYER HEALTHCARE AG.: EP1716248 (2006).
   Google Scholar
• BAYER HEALTHCARE AG.: EP1664790 (2006).
   Google Scholar
• BAYER HEALTHCARE AG.: WO2005022164 (2005).
   Google Scholar
• BAYER HEALTHCARE AG.: US2007081997 (2007).
   Google Scholar
• BAYER HEALTHCARE AG.: EP1664331 (2006).
   Google Scholar
• BAYER HEALTHCARE AG.: WO2005118840 (2005).
   Google Scholar
• BAYER HEALTHCARE AG.: WO2005021741 (2005).
   Google Scholar
• BAYER HEALTHCARE AG.: EP1664290 (2006).
   Google Scholar
• BAYER HEALTHCARE AG.: WO2005075634 (2005).
   Google Scholar
• BAYER HEALTHCARE AG.: EP1711601 (2006).
   Google Scholar
• BAYER HEALTHCARE AG.: US2007148175 (2007).
   Google Scholar
• BAYER HEALTHCARE AG.: WO2005022146 (2005).
   Google Scholar
• BAYER HEALTHCARE AG.: EP1664791 (2006).
   Google Scholar
• BAYER HEALTHCARE AG.: WO2005075664 (2005).
   Google Scholar
• BAYER HEALTHCARE AG.: EP1711616 (2006).
   Google Scholar

Websites

• http://merops.sanger.ac.uk The MEROPS peptidase database is a central information resource for proteolytic enzymes and the proteins that inhibit them. This database uses an hierarchical, structure-based classification, hence each proteolytic enzyme is assigned to a family (on the basis of statistically significant similarities in amino acid sequence) and families that are thought to be homologous are grouped together in a clan, as detailed in the text.
   Google Scholar
• http://www.gene.ucl.ac.uk/nomenclature Each human gene is given a unique approved symbol and stored in the HGNC (human gene nomenclature committee) database to facilitate the search and retrieval of information.
   Google Scholar